Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel combination neoadjuvant chemotherapy for HER2-positive inflammatory breast cancer: a case report.

Selected inflammatory breast cancer research published in 2017

What is an abstract?
An abstract is a brief summary of a research article, thesis, review, conference proceeding, or any in-depth analysis of a particular subject and is often used to help the reader quickly ascertain the paper’s purpose. The abstract can convey the main results and conclusions of a scientific article but the full text article must be consulted for details of the methodology, the full experimental results, and a critical discussion of the interpretations and conclusions.

The abstract below is edited for length. Read the free complete article on PubMed Central.

Yamashita, Y., et al. (2017) Effectiveness of Pertuzumab, Trastuzumab, and Docetaxel Combination Neoadjuvant Chemotherapy for HER2-Positive Inflammatory Breast Cancer: A Case Report. Breast Care (Basel). 2017 Mar;12(1):45-47. doi: 10.1159/000457948.

Inflammatory breast cancer (IBC) is the most aggressive form of primary breast cancer.
To improve the poor prognosis of IBC, combined modality therapy is required, including chemotherapy and local treatment such as surgery and/or radiation therapy. In this case, combination neoadjuvant chemotherapy with PTD for HER2-positive IBC was effective, and this regimen may contribute to further improvements in the cure rate for this malignancy.

Previous article: Next article: